InMed Pharmaceuticals, Inc. (IMLFF)

Our latest clients all have the potential to grow significantly in the near and long-term future

InMed Pharmaceuticals, Inc. (IMLFF)

Postby QualityStocks » Fri Mar 03, 2017 1:07 pm

InMed Pharmaceuticals, Inc. (IMLFF) is a preclinical-stage biopharmaceutical company specializing in the development of novel therapeutics leveraging the pharmacological benefits of cannabinoids. Utilizing its proprietary bioinformatics assessment tool, InMed aims to identify bioactive compounds found within the cannabis plant that have the potential to offer optimized therapeutic benefit while demonstrating limited adverse effects. This assessment tool, in combination with the company's cannabinoid biosynthesis technology and drug development pipeline, serves as InMed's fundamental value driver.

Bioinformatics is a proprietary, computer-based program designed to assist in the identification of novel cannabinoids using comprehensive algorithms to integrate data from numerous bioinformatics databases, as well as a database on the structure of currently approved pharmaceutical products and an extensive database on over 90 individual cannabinoid drugs found in cannabis. This extensive collection of data is derived from both public and propriety-based sources. Leveraging this tool, the company aims to create associations between approved pharmaceuticals and cannabinoids with similar structures in order to identify active cannabinoids that have the potential to treat specific diseases. Per InMed's website, this type of bioinformatics assessment represents "significant promise for future drug discovery, as it integrates many data sets and builds holistic models to approach a specific disease."

After discovering these promising active cannabinoids, InMed moves to test and confirm their activity in biological systems through in vitro and in vivo experimentation. It is at this stage of development that the company's proprietary biosynthesis process of cannabinoid manufacturing will be most promising. InMed is currently developing a robust, high-yield biosynthesis process for manufacturing all 90+ naturally-occurring cannabinoids. By modifying the agriculture-based formula for harvesting cannabinoids, InMed aims to combine the inherent safety and known efficacy of the natural drug structure with the convenience, control and quality of 21st Century laboratory-based manufacturing processes.

The company's pipeline currently includes two drug candidates in preclinical development, including INM-750 for the treatment of epidermolysis bullosa (EB) and INM-085 for the treatment of glaucoma. Referred to by the Dystrophic Epidermolysis Bullosa Research Association of America as "The Worst Disease You've Never Heard Of," EB is a rare genetic connective tissue disorder that affects roughly one out of every 20,000 births in the United States. The condition currently has no approved treatment or cure. Through the development of INM-750, InMed is attempting to address this significant unmet medical need. The drug candidate replaces missing keratins in the skin with specially selected cannabinoids in an effort to modulate the painful manifestations of EB.

INM-085, InMed's second development candidate, is formulated to reduce the elevated intra-ocular pressure that is often associated with glaucoma. Additionally, the cannabinoids utilized in INM-085 are expected to provide neuroprotection for the retinal ganglion cells and other optic nerve tissues following topical administration. Although it is still in preclinical development, INM-085 targets a sizable market. According to the Glaucoma Research Foundation, glaucoma is a leading cause of blindness with no approved cure. The National Institutes of Health estimates that more than 3 million Americans currently have glaucoma, and more than 120,000 have been blinded by the disease.

InMed is focused on progressing toward validation of its drug candidate selection, using data to secure its patents and developing key disruptive technologies. In 2016, the company was successful in completing financings of $1.9 million. In January 2017, InMed completed a non-brokered private placement of common shares generating aggregate gross proceeds of C$1.5 million, strongly positioning the company to attract the new investment required to fund its aggressive growth strategies in 2017.

The company's management team has well over a century of combined experience in the biopharmaceutical space. Company CEO Eric Adams has more than 25 years of experience in company and capital formation, global market development, mergers and acquisitions, licensing and corporate governance. During his time as CEO of enGene Inc., he led the gene therapy startup to a position at the head of the industry.

Joining Adams on the InMed management team are Chief Scientific Officer Dr. Sazzan Hossain; Senior Vice President, Clinical and Regulatory Affairs Alexandra D.J. Mancini; SVP, Corporate Strategy & Investor Relations Chris Bogart; and Chief Financial Officer Jeff Charpentier, as well as Chief Medical Officer Dr. Ado Muhammed, MD, DPM, MFPM.

Muhammed, in particular, has an extensive history in the pharmaceutical industry, having previously served as an executive of GW Pharmaceuticals, a global leader in the development of cannabinoid-based medicines. During his time as Associate Medical Director of that company, Muhammed played an instrumental role in the development and FDA approval of one of the first cannabis drugs. This GW Pharmaceuticals development program coincided with a sharp rise in share price from less than $9 in 2013 to more than $129 today, with the company's current market value totaling more than $2.9 billion. Investment Considerations Extensive portfolio of assets in dermatology, ocular disease and additional indications and cannabinoid biosynthesis Positioned to achieve value-driving, near-term corporate milestones with limited investment Led by a management team of experienced professionals capable of building value in biopharmaceuticals Additional Resources Newsroom Presentation Website
The QualityStocks Daily Newsletter http://Newsletter.QualityStocks.net

The QualityStocks Daily Blogs http://Blog.QualityStocks.net

Please read FULL Compensation Disclosures and other disclaimers at http://www.qualitystocks.net/disclaimer.php
QualityStocks
Site Admin
 
Posts: 194
Joined: Mon May 21, 2007 7:58 pm
Location: Scottsdale, AZ

Re: InMed Pharmaceuticals, Inc. (IMLFF)

Postby QualityStocks » Wed Mar 15, 2017 5:54 pm

Biotech Innovations Drive Cannabinoid-Based Pharmaceutical Market Growth

As the medical marijuana market continues to grow, so does the number of biotech companies expanding their research into the development of innovative cannabinoid-based pharmaceuticals and delivery systems. It is estimated that the U.S. consumer market for cannabinoid pharmaceuticals will increase exponentially in upcoming years, exceeding $50 billion by 2029, according to Statista. This doesn’t appear to be a lofty forecast, given the prominence this market segment has gained by the sustained efforts and innovations of leading biotech companies such as InMed Pharmaceuticals, Inc. (IMLFF) (InMed Profile), GW Pharmaceuticals plc (GWPH), Zynerba Pharmaceuticals, Inc. (ZYNE), AXIM® Biotechnologies, Inc. (AXIM) and OWC Pharmaceutical Research Corp. (OWCP). From multiple sclerosis symptoms to gastrointestinal problems and rare skin conditions, cannabinoids are increasingly demonstrating potential for a variety of medical conditions. The biotech companies developing and commercializing these new therapies are on a path to market stardom.

Topical delivery, targeting to treat diseases on a local (rather than systemic) basis, is a preferred approach for various cannabinoid therapies, especially those targeting skin conditions. Canada-based InMed Pharmaceuticals, Inc. (IMLFF) (InMed Profile), flagship product, INM-750, is a cannabinoid-based topical therapy for a rare skin condition called Epidermolysis Bullosa (EB). INM-750 is the first treatment ever developed specifically for this disease. Although, as of now, there is no cure for EB, INM-750 has the potential to accelerate wound healing and skin regeneration; alleviate several symptoms such as inflammation, itching and pain; and modulate keratin levels in the skin, with potentially regenerative and restorative effects. With a potential global market of $1 billion per year, the treatment is being developed for topical application so as to maximize efficacy while minimizing side effects. InMed’s second product candidate, INM-085, is targeting glaucoma and is also being developed for topical (eye drop) application. With an estimated 2.7 million patients in the U.S. and a global market exceeding $5 billion, INM-085 will be the first glaucoma treatment designed to be a multi-mechanism, multi-target of action therapy based on cannabinoids.

In addition to its innovative drug delivery systems, what sets InMed apart further is its groundbreaking, proprietary biosynthesis process for the manufacture of all 90+ known cannabinoids that occur naturally in the marijuana plant. This cost-effective, innovative approach has already proven successful at laboratory scale, and it is likely to make InMed a game-changer in the booming cannabinoid pharmaceutical market. Most biotech companies in the field, including giants such as GW Pharmaceuticals (GWPH), focus on traditional cannabinoid extraction methods that require tons of marijuana plants and tens of millions of dollars in expenses. This costly process is also resource intensive, with various factors that can impact quality control, just to get the two most common cannabinoids: tetrahydrocannabinol (THC) and cannabidiol (CBD). The extraction of less common cannabinoids is even more expensive, making such traditional processing methods highly unfeasible.

But InMed’s biosynthesis process, much like Eli Lilly’s current method for making human insulin, can change all of that. The company’s high-yield/low-cost approach will allow the industry to tap into the potential of cannabinoids present in marijuana plants by creating them in a laboratory setting in a safe and scalable manner. With its top-tier management and board, which includes Chief Scientific Officer and global leader in cannabinoid science Dr. Sazzad Hossain and Chief Medical Officer Ado Muhammed – a former senior member of GW Pharmaceuticals and a proven leader in the development of cannabinoid-based therapies, InMed has the right expertise, the right team and the right science to cause a major shift in the market and turn it into a billion-dollar business.

Another company that focuses on transdermal cannabinoid-based therapies with very encouraging results is Israel’s OWC Pharmaceutical Research Corp. (OWCP). The company manufactures products for various conditions, including PTSD, multiple myeloma, migraines and psoriasis, and it is focused on the development and optimization of two proprietary delivery systems: a sublingual tablet and a topical compound. OWC’s research efforts are spearheaded by Chief Science Officer Dr. Yehuda Baruh, former head of the medical cannabis program of the Israeli Ministry of Health for over 10 years. Last month, the company received Institutional Board Review approval to run safety testing on its topical cream for the treatment of psoriasis and related conditions, making it the first topical delivery mechanism and proprietary cannabinoid-based psoriasis formulation to be included in the NIH Registry.

Yet another innovative delivery method for cannabinoid-based therapies comes from AXIM® Biotechnologies, Inc. (AXIM). With a market cap of $490 million, AXIM® is a leading cannabinoid research and development company that focuses on creating pharmaceutical, cosmetic and nutraceutical products. Its pharmaceutical products target mostly pain, anxiety and spasticity, as well as other medical conditions that can benefit from cannabinoid-based treatments. Its flagship products both use an innovative delivery method, being manufactured in the form of chewing gum, including: CanChew® – a CBD-based controlled release product for the treatment of irritable bowel syndrome (IBS), and MedChew Rx – a CBD/THC combination currently undergoing clinical trials for the treatment of multiple sclerosis-associated pain and spasticity. The company recently announced the launch of a phase 2 clinical trial for CanChew Plus®, which enrolls 40 trial patients suffering from IBS.

Another successful cannabis biotech company, Zynerba Pharmaceuticals, Inc. (ZYNE), has taken the process one step further, focusing on the development of novel synthetic cannabinoid treatments designed for transdermal delivery. With a market cap of more than $260 million and a stock price of over $20 per share, Zynerba is developing two proprietary therapies: a synthetic tetrahydrocannabinol pro-drug transdermal patch for peripheral neuropathic pain and fibromyalgia, and a transdermal synthetic cannabinoid gel for osteoarthritis, fragile X syndrome and refractory epilepsy. Earlier this year, the company launched an underwritten public offering of 2.8 million shares at $18 per share, with expected proceeds of over $50 million to continue funding the clinical development of its proprietary therapies.

As mentioned above, GW Pharmaceuticals plc (GWPH) is a leading industry player and a clear example of a medical marijuana firm whose stock has been skyrocketing as a result of successfully isolating different cannabinoids from marijuana plants and turning them into efficient medical therapies. The UK-based biopharmaceutical company has discovered an oromucosal spray for multiple sclerosis spasticity, which is already being successfully marketed in dozens of countries. Furthermore, it has isolated another cannabinoid to be used for the treatment of epilepsy, which is currently in the final clinical trial states before approval, and the company is also developing other product candidates for a wide range of medical conditions such as tuberous sclerosis complex, Dravet syndrome, infantile spasms, Lennox-Gastaut syndrome, glioma and schizophrenia. The company’s success in developing effective and innovative cannabinoid-based therapies over the last few years has earned it a market cap of more than $3 billion and a share price of over $120.

For more information on InMed Pharmaceuticals, Inc. (IMLFF) please visit: https://www.inmedpharma.com/insights/2017
The QualityStocks Daily Newsletter http://Newsletter.QualityStocks.net

The QualityStocks Daily Blogs http://Blog.QualityStocks.net

Please read FULL Compensation Disclosures and other disclaimers at http://www.qualitystocks.net/disclaimer.php
QualityStocks
Site Admin
 
Posts: 194
Joined: Mon May 21, 2007 7:58 pm
Location: Scottsdale, AZ

Re: InMed Pharmaceuticals, Inc. (IMLFF)

Postby QualityStocks » Thu Mar 16, 2017 4:13 pm

InMed Pharmaceuticals (IMLFF) Lead Product Candidate Targeting Rare, Incurable Skin Disease

With a prevalence of 20 per million newborns in the United States, and an estimated 500,000 patients worldwide, epidermolysis bullosa is a group of rare inherited skin diseases that range in severity from mild to lethal and have no currently approved or known cure or treatment. The condition was brought to the public attention in the early 2000s, and, since then, efforts to find a cure have not born fruit, with most research and development focusing instead on addressing the symptoms, such as reducing blistering and swelling and preventing wounds and pain. However, a new product currently in development by Vancouver-based biopharmaceutical company InMed Pharmaceuticals, Inc. (OTCQB: IMLFF) may change that, having the potential to basically reverse the disease.

The condition causes extreme skin sensitivity that often results in painful blisters on the dermis or mucosal membranes, as a result of minor trauma such as heat or scratching or friction. Usually showing up in infancy or early childhood, the disease has various symptoms such as the appearance of large blisters on the skin, mostly on the feet and hands; loss of fingernails or toenails; blistering in the respiratory system, blistering on the scalp and hair loss; difficulty swallowing; dental problems and more. In its more severe forms, epidermolysis bullosa can cause complications such as sepsis, malnutrition and anemia, dehydration, eye disorders and even skin cancer. In some severe cases where blistering is widespread, frequent infections and sores affect the patients’ ability to breathe and eat and ultimately result in their death.

This orphan disease has no known treatment, and it is therefore a significant unmet medical need that InMed Pharmaceuticals, focusing on the research and development of innovative cannabinoid-based therapies, is working to fill. According to InMed, cannabinoid compounds have recognized analgesic, anti-inflammatory, and wound healing properties, which make them excellent candidates to alleviate some of the symptoms associated with this condition.

The company’s lead product candidate, INM-750, is the first therapy developed specifically for epidermolysis bullosa, being designed both to alleviate symptoms and target dermis imbalances that may ultimately provide a cure. INM-750 targets cannabinoid receptors in the skin to help accelerate wound healing, reduce pain and itching, reduce inflammation, and more. By upregulating specific keratins in the skin, INM-750 may also help reestablish the epidermal junction and essentially reverse the condition for patients with epidermolysis bullosa simplex (EBS) – the most common form of the disease.

Earlier this month, InMed filed an international Patent Cooperation Treaty application for intellectual and commercial protection of INM-750 and a cannabinoid-based therapy for EBS. This marks a significant milestone for the company, serving as validation for its efforts to develop new therapies based on cannabinoids and its unique approach to drug development. The company is using a proprietary bioinformatics assessment tool to identify what bioactive cannabis compounds can offer the optimal therapeutic benefits, with limited side effects and a proprietary biosynthesis technology to manufacture and test these compounds in biological systems via in vitro and in vivo experimentation. These proprietary systems and its drug development pipeline are the company’s core assets.

For more information, visit the company’s website at www.InMedPharma.com
The QualityStocks Daily Newsletter http://Newsletter.QualityStocks.net

The QualityStocks Daily Blogs http://Blog.QualityStocks.net

Please read FULL Compensation Disclosures and other disclaimers at http://www.qualitystocks.net/disclaimer.php
QualityStocks
Site Admin
 
Posts: 194
Joined: Mon May 21, 2007 7:58 pm
Location: Scottsdale, AZ


Return to QualityStocks Featured Companies

Who is online

Users browsing this forum: No registered users and 1 guest

cron